V-VCD Study (AMaRC 18-01)
An exploratory study of Venetoclax in combination with Bortezomib-Cyclophosphamide-Dexamethasone (VCD) induction therapy in newly diagnosed transplant eligible (NDTE MM) multiple myeloma with proteomic correlative studies.
The primary aim of this trial is to determine the rate of complete response achieved by using Venetoclax and VCD.
For more information please visit
Australasian Myeloma Research Consortium (AMaRC C/- Alfred Health)
Other (specify below)
Parts of research done:
Literature review, Research proposal, Ethics approval